Say goodbye to extreme anxiety

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Innovations Group (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.

The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care, according to the Chief Science Officer.

The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).

PDF of article